reports
- Christian Arnold
- Christian Arnold
- ING Helpdesk
- Usama Tariq
- Wim Gille
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Livio Luyten
- Michiel Declercq
- Thibault Leneeuw
- Wim Lewi
- Kristof Samoy
NX Filtration Trouble comes in fours, yet another profit warning erodi...
NX Filtration just sent out another profit warning. For the fourth time in a row the company confessed it will not be able to realise its issued revenue guidance. At the 1H25 release the company reiterated its FY25 revenue guidance calling for y/y growth in the 50-70% range with KBC est. at the 60% midpoint. Today management warns FY25 revs are expected to be ca. €14m, representing a y/y growth just topping 25%. No quantified insights in profitability and cash position were given but surprisingl...
IBA acquires ORA expanding its strategic leadership in Nuclear Medicin...
IBA acquires ORA expanding its strategic leadership in Nuclear Medicine Louvain-La-Neuve, Belgium, 19 December 2025 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology with a preeminent position in nuclear medicine, acquires ORA, a global trailblazer in radiochemistry based in Belgium. This acquisition emphasizes IBA’s long-term commitment to the fast-developing and promising field of nuclear medicine. It reinforces IBA’s position at the forefront of innovation in precision oncology enabling for better diagnostic and more personalized patient...
Avec l’acquisition d’ORA, IBA renforce son leadership stratégique en m...
Avec l’acquisition d’ORA, IBA renforce son leadership stratégique en médecine nucléaire Louvain-la-Neuve, Belgique, le 19 décembre 2025 - IBA (Ion Beam Applications S.A., EURONEXT), leader mondial des technologies d’accélération de particules et acteur de premier plan en médecine nucléaire, acquiert ORA, pionnier mondial de la radiochimie, basé en Belgique. Cette acquisition illustre l'engagement à long terme d'IBA dans le domaine en pleine expansion et à fort potentiel de la médecine nucléaire. Elle consolide la position d'IBA à l’avant-garde de l'innovation en oncologie de précision, p...
- ING Helpdesk
- Hilde Van Boxstael
- Jacob Mekhael
- Livio Luyten
- Michiel Declercq
- Thomas Couvreur
- Wim Hoste
- Wim Lewi
- Jacob Mekhael
argenx Vyvgart phase 3 in TED stopped due to lack of efficacy
argenx announced that the phase 3 (UplighTED) studies evaluating Vyvgart subcutaneous (SC) in adults with moderate to severe thyroid eye disease (TED) will be discontinued following a pre-specified unblinded interim analysis from patients completing 24 weeks of treatment. The decision to stop the trial due to lack of efficacy in TED is disappointing, however, the company notes that its pipeline strategy anticipates attrition. Of the 2026 phase 3 readouts, TED was the only program where argenx le...
La protonthérapie, nouvelle norme de soins pour les patients atteints ...
La protonthérapie, nouvelle norme de soins pour les patients atteints d'un cancer de l'oropharynx Louvain-la-Neuve, Belgique, le 15 décembre 2025 - IBA (Ion Beam Applications S.A., EURONEXT), le leader mondial des technologies d’accélération de particules et principal fournisseur de solutions de protonthérapie pour le traitement du cancer, a le plaisir d'annoncer aujourd'hui que The Lancet – l'une des revues scientifiques les plus renommées au monde – a publié, le 11 décembre, une étude historique recommandant la protonthérapie comme nouvelle norme de soins pour les patients atteints d'...
argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyr...
argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease 15 December, 2025, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the Phase 3 UplighTED studies evaluating efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) in adults with moderate to severe thyroid eye disease (TED) will be discontinued. The decision is based on the recommendation from an Independent Data Monitoring ...
Proton Therapy New Standard of Care for Patients with Oropharyngeal Ca...
Proton Therapy New Standard of Care for Patients with Oropharyngeal Cancer Louvain-La-Neuve, Belgium, December 15, 2025 – (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer, is pleased to share today that, on December 11, The Lancet – one of the world’s most renowned academic journals – published a landmark study that recommends proton therapy as a new standard of care for patients with oropharyngeal cancer. , led by MD Anderson Cancer Center, the world’s ...
- ING Helpdesk
Benelux Morning Notes
Belgian Telecoms: DIGI Belgium CEO Interview: ‘We are running a marathon, not a sprint' IBA: IBA to install a Rhodotron in East China. Ontex: Another quarter, another profit warning. Theon International: Backlog visibility indeed. Xior: 2026 outlook positive but with no major surprise. Events Calendar
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Livio Luyten
- Mathijs Geerts Danau
- Michiel Declercq
- Wim Hoste
- Wim Lewi
China Gold Irradiation Introduces IBA’s sustainable X-ray irradiation ...
China Gold Irradiation Introduces IBA’s sustainable X-ray irradiation technology to expand its production capacity Louvain-la-Neuve, Belgium, December 11, 2025 – (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and electron beam and X-ray solutions for industrial advanced irradiation, announced today it has signed a contract with China Gold Irradiation (CGI), the largest high standard irradiation service company in China, to install a Rhodotron® in Jiaxing, Zhejiang Province, as a first step of the transition of China’s irradiation processing in...
China Gold Irradiation adopte la technologie d'irradiation par rayons...
China Gold Irradiation adopte la technologie d'irradiation par rayons X d'IBA afin d'accroître ses capacités de production Louvain-la-Neuve, Belgique, le 11 décembre 2025 - IBA (Ion Beam Applications S.A.), le leader mondial des technologies d’accélération de particules et des solutions d'irradiation industrielle par faisceau d'électrons et rayons X, annonce aujourd'hui avoir signé un contrat avec China Gold Irradiation (CGI), la plus grande société de services d'irradiation haut de gamme en Chine, pour l'installation d'un Rhodotron® à Jiaxing, dans la province du Zhejiang. Cet accord ré...
- ING Helpdesk
- Hilde Van Boxstael
- Mathijs Geerts Danau
- Michiel Declercq
- Thomas Couvreur
- Wim Hoste
- Wim Lewi
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.